Innoviva, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Innoviva reported Q3 2026 total revenue of $106.1M (down 1.6% YoY), with U.S. net product sales from Innoviva Specialty Therapeutics (IST) reaching $43.3M, up 45% YoY from $29.9M in Q3 2025. GSK royalty revenue remained flat at $58.1M. The company repurchased 1.2M shares for $26.3M in Q3 under its $125M program (3.8M shares/$82.7M repurchased year-to-date). However, a $139.5M unrealized loss on strategic investments (primarily Armata Pharmaceuticals decline) drove a net loss of $73.9M ($1.03 loss per share), despite operating income of $42.2M (+21.9% YoY).
Why this rating
IST momentum (+45% sales growth, NUZOLVENCE launch) offsets flat royalties; mark-to-market losses on strategic holdings ($535.5M portfolio, 35% of market cap) create accounting noise masking operational strength; buyback signals confidence but is modest capital return relative to size.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.